Company Encyclopedia
View More
name
IGM Biosciences
IGMS.US
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010.
1.946 T
IGMS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking0/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-47.82%E
    • Profit Margin-36.80%E
    • Gross Margin99.10%A
  • Growth ScoreB
    • Revenue YoY4882.82%A
    • Net Profit YoY75.78%A
    • Total Assets YoY-68.21%E
    • Net Assets YoY-17.51%E
  • Cash ScoreB
    • Cash Flow Margin-271.71%D
    • OCF YoY4882.82%A
  • Operating ScoreB
    • Turnover0.65B
  • Debt ScoreA
    • Gearing Ratio5.66%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    11:31 ET Flagship Pioneering Appoints Mary Beth Harler President of Pioneering Medicines

    Flagship Pioneering has appointed Dr. Mary Beth Harler as President of Pioneering Medicines, its drug discovery unit. Dr. Harler brings over 20 years of experience in biotechnology and pharmaceuticals, previously serving as CEO of IGM Biosciences and holding senior roles at Bristol Myers Squibb. She will lead efforts to develop novel therapeutics from Flagship's innovative bioplatforms, collaborating with internal teams and external partners. Dr. Harler expressed excitement about transforming groundbreaking bioplatforms into medicines for unmet medical needs.

    prnewswire·
    US
    IGMS
    0.00%
    US
    BMY
    0.00%
    prnewswire·
    US
    IGMS
    0.00%
    US
    BMY
    0.00%

    Mackenzie Investments Announces September 2025 Quarterly Distributions For Its Exchange Traded Funds

    Mackenzie Investments has announced the quarterly cash distributions for its equity Exchange Traded Funds (ETFs) for September 2025. Unitholders of record on September 22, 2025, will receive distributions payable on September 29, 2025. The announcement includes specific per-unit distribution amounts for various ETFs listed on the Toronto Stock Exchange. Mackenzie Investments manages approximately $231 billion in assets and is part of IGM Financial Inc.

    Reuters·
    US
    IGMS
    0.00%
    Reuters·
    US
    IGMS
    0.00%

    Wall Street Zen Upgrades IGM Biosciences (NASDAQ:IGMS) to Hold

    Wall Street Zen has upgraded IGM Biosciences (NASDAQ:IGMS) to a "hold" rating. The stock opened at $1.27, with a 52-week range of $0.92 to $22.50. IGM reported earnings of $1.58 per share, surpassing estimates. The company has a market cap of $76.57 million and a negative return on equity of 93.35%. Several hedge funds have recently increased their stakes in IGM. IGM develops IgM antibodies for cancer and autoimmune diseases, including Aplitabart and imvotamab.

    Market Beat·
    US
    IGMS
    0.00%
    Market Beat·
    US
    IGMS
    0.00%

    IGM Biosciences, Inc. (NASDAQ:IGMS) Given Average Rating of "Reduce" by Analysts

    IGM Biosciences, Inc. (NASDAQ:IGMS) has received a consensus rating of "Reduce" from ten analysts, with one sell rating and nine hold ratings. The average one-year price target is $5.50. The stock opened at $1.27, with a 52-week range of $0.92 to $22.50. The company reported $1.58 EPS for the last quarter, exceeding estimates. Institutional investors own 42.79% of the stock. IGM Biosciences develops IgM antibodies for cancer and autoimmune diseases.

    Market Beat·
    US
    IGMS
    0.00%
    Market Beat·
    US
    IGMS
    0.00%

    IGM Biosciences Announces Delisting from Nasdaq Following Merger Completion

    IGM Biosciences Inc. has announced its delisting from Nasdaq following its acquisition by Concentra Biosciences, LLC, which was finalized on August 14, 2025. The company requested the delisting of its common stock, leading to the suspension of trading and the filing of a Notification of Removal from Listing with the SEC. IGM will also terminate the registration of its shares and suspend reporting obligations under the Securities Exchange Act of 1934, as it becomes a wholly-owned subsidiary of Concentra.

    Reuters·
    US
    IGMS
    0.00%
    Reuters·
    US
    IGMS
    0.00%
    © 2025 Longbridge｜Disclaimer